
    
      Compare the efficacy and safety of viramidine 600 mg twice a day (BID) versus ribavirin
      1000/1200 mg/day, both drugs administered in combination with pegylated interferon alfa-2a to
      treatment-naive patients with chronic hepatitis C (CHC)
    
  